As the scientists reported Monday in Annals of Internal Medicine, they didn’t find any. Which means that the woman, who they are calling the “Esperanza Patient” to protect her privacy, appears to have eradicated the deadly virus from her body without the help of drugs or a bone marrow transplant — which would make her only the second person believed to have cured herself of HIV, without drugs or any other treatment.
“This gives us hope that the human immune system is powerful enough to control HIV and eliminate all the functional virus,” said Xu Yu, an immunologist at the Ragon Institute of MGH, MIT, and Harvard and senior author on the new report. “Time will tell, but we believe she has reached a sterilizing cure.” The discovery, which was previously announced at the Conference on Retroviruses and Opportunistic Infections in March, could help identify possible treatments, researchers said.
Several Covid-19 vaccines under development in Israel hold out promise for their ability to protect against variants of the virus that are challenging existing vaccines.
Back in May 2020, research groups across the world were racing to formulate vaccines against the SARS-CoV-2 coronavirus.
Realizing it was not going to win that race, Israel purchased millions of Pfizer-BioNTech and Moderna mRNA vaccines from the United States and led the world in getting eligible citizens vaccinated.… See more.
Injectable and oral vaccines under development in Israel may prove significant in protecting people from mutations of the SARS-CoV-2 coronavirus.
LifeArc scientists, in collaboration with researchers in the UK and Germany, have developed a promising new approach to potentially treat Alzheimer’s disease – and also vaccinate against it.
Both the antibody-based treatment and the protein-based vaccine developed by the team reduced Alzheimer’s symptoms in mouse models of the disease. The research is published today in Molecular Psychiatry.
LifeArc and researchers in the UK & Germany have developed a promising new approach to potentially treat Alzheimer’s.
The development of a genetic code expansion-based system enables fast protein expression in response to a noncanonical amino acid. The system was implanted into diabetic mice to rescue hyperglycemia with oral delivery of the amino acid.
The new form of war is already here and most don’t realize it.
Thanks to Hone for sponsoring this video! Go to https://honehealth.com/thoughty2 to get your home assessment test and a doctor’s consultation for only $45!
Get my new book Bread and Circuses: https://bit.ly/breadandcircusesbook.
Listen to my new podcast Random Interesting Facts: http://bit.ly/RIFThoughty2 Or watch it on YouTube: http://bit.ly/RIFPodcastYT
Thoughty2 Audiobook: https://geni.us/t2audio. Thoughty2 Book: https://geni.us/t2book. Support Me & Get Early Access: http://bit.ly/t2club. Thoughty2 Merchandise: https://bit.ly/t2merch.
About Thoughty2 Thoughty2 (Arran) is a British YouTuber and gatekeeper of useless facts. Thoughty2 creates mind-blowing factual videos about science, tech, history, opinion and just about everything else. #Thoughty2
Researchers have identified a version of a gene that doubles a person’s risk of severe COVID-19 and doubles the risk of death from the disease for people under 60.
The new Covid pills from Merck and Pfizer offer a ton of promise. But there’s plenty we still don’t know about how well they work.
The last year has been a story of triumph in the vaccine world, with the rapid development of two highly successful vaccines for Covid-19, one developed by Moderna and the other by Pfizer and BioNTech. Now that flu season is approaching, why are we still using 50-year-old technology for the flu vaccine?
The reason the Covid-19 vaccines were developed so quickly is that they used a new, much faster and easier-to-create type of vaccine technology, based on messenger RNA, or mRNA. What’s even more exciting is that we now have an overwhelming amount of evidence, from real-world experience, that these vaccines are remarkably safe and effective.
Now, anti-vaxxers and the “vaccine hesitant” are claiming they don’t trust the vaccine because it was developed too fast. That’s ridiculous: the real reason they don’t trust the vaccine is because they’re consuming a steady diet of anti-vaccine nonsense, promoted by a combination of right-wing media and the Disinformation Dozen (who include left-wing as well as right-wing zealots). But let’s not go down that rabbit hole today.
I may have already posted about this, but this is more data from The Lancet.
Background.
Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to COVID-19.
Methods.
This placebo-controlled, randomised, adaptive platform trial done among high-risk symptomatic Brazilian adults confirmed positive for SARS-CoV-2 included eligible patients from 11 clinical sites in Brazil with a known risk factor for progression to severe disease. Patients were randomly assigned (1:1) to either fluvoxamine (100 mg twice daily for 10 days) or placebo (or other treatment groups not reported here). The trial team, site staff, and patients were masked to treatment allocation. Our primary outcome was a composite endpoint of hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to tertiary hospital due to COVID-19 up to 28 days post-random assignment on the basis of intention to treat. Modified intention to treat explored patients receiving at least 24 h of treatment before a primary outcome event and per-protocol analysis explored patients with a high level adherence (80%). We used a Bayesian analytic framework to establish the effects along with probability of success of intervention compared with placebo. The trial is registered at ClinicalTrials dot gov (NCT04727424) and is ongoing.
Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to a tertiary hospital.
Fastgrants and the rainwater charitable foundation.
For the Portuguese translation of the abstract see Supplementary Materials section.
Creating a world where no woman has to die giving life — temitayo erogbogbo, global advocacy director, MSD for mothers, merck sharp & dohme.
Mr. Temitayo (Tayo) Erogbogbo, is Global Advocacy Director of MSD for Mothers (https://www.msdformothers.com/), at Merck Sharp & Dohme.
Tayo has two decades of combined private sector and international development experience, 13 years of which was spent in the pharmaceutical industry in multiple roles across community relations, government affairs, marketing and sales.
As the Global Advocacy Director of MSD for Mothers, Tayo is responsible for global and national strategic partnerships and programs to bring about policies and practice changes to improve maternal health care, and strengthen health systems, particularly where private sector approaches can be leveraged for greater impact.
Prior to MSD for Mothers, Tayo led the establishment of an adolescents and youth constituency at The Partnership for Maternal, Newborn and Child Health (PMNCH), a multi-constituency partnership hosted by the World Health Organization, to advocate for better sexual, reproductive, maternal, newborn, child, and adolescent health policies and services at global, regional, and national levels. Additionally, he contributed to the development of the Global Strategy for Women’s, Children’s, and Adolescents’ Health 2016–2030.
Previously, in collaboration with multi-sectoral partners in Nigeria, he contributed to the passage of the National Health Bill, the development of the National Gender Policy Guidelines and the passage of Violence Against Person’s Prohibition in support of gender equality. Tayo also spearheaded Abbott’s HIV patient relations function within Europe, developing services to support people living with HIV by partnering with community organizations. He advocated for anti-retroviral drug access across Africa and developed a health care professional (HCP) train-the-trainer program that has educated over 3,000 HCPs.
Tayo earned a BSc in Management Sciences from Loughborough University, and a MSc in Information Technology for Management from Coventry University.
Tayo is also an elite athlete in the Triple Jump with a Bronze medal at the European U23 Championships.
